Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 13/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.33 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | CSF1R | P07333 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7952504 | 0.85 | CA12 (0.35) | ALDH1A1CYP3A4CYP2D6TSHRABCC8 | |
| SCHEMBL7952830 | 0.81 | CA12 (0.36) | ALOX5ALDH1A1LMNACYP1A2CYP3A4 | |
| SCHEMBL7951006 | 0.81 | CA12 (0.39) | ALDH1A1LMNACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL722051 | 0.81 | ABCC8 (0.48) | ALDH1A1LMNACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL7950842 | 0.80 | CXCR2 (0.36) | ALDH1A1LMNACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL7953046 | 0.77 | CA1 (0.35) | ALDH1A1LMNACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL7952481 | 0.77 | HCAR3 (0.43) | ALDH1A1LMNACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL718189 | 0.76 | CA12 (0.57) | ALDH1A1LMNATHRBCA12CA1 | |
| SCHEMBL722204 | 0.75 | ABCC8 (0.61) | ALDH1A1LMNACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL7951782 | 0.74 | ALDH1A1 (0.36) | ALDH1A1LMNACYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1222910-A | 1,2, 4-benzothiadiazine derivatives, method for preparing same and use thereof | NOVO NORDISK AS (DK) | 1999-07-14 | — | — | CN | claimed |
| US-11505572-B2 | Therapeutics for the treatment of glaucoma | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2022-11-22 | — | — | US | disclosed |
| US-10981951-B2 | Therapeutics for the treatment of glaucoma | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2021-04-20 | — | — | US | disclosed |
| US-20210040148-A1 | THERAPEUTICS FOR THE TREATMENT OF GLAUCOMA | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2021-02-11 | — | — | US | disclosed |
| US-20170002040-A1 | NOVEL THERAPEUTICS FOR THE TREATMENT OF GLAUCOMA | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2017-01-05 | — | — | US | disclosed |
| CN-1081633-C | 1,2, 4-benzothiadiazine derivatives, method for preparing same and use thereof | NOVO NORDISK AS (DK) | 2002-03-27 | — | — | CN | disclosed |
| US-6242443-B1 | 1,2,4-benzothiadiazine derivatives, their preparation and use | NOVO NORDISK AIS (DK) | 2001-06-05 | — | — | US | disclosed |
| CN-1222910-A | 1,2, 4-benzothiadiazine derivatives, method for preparing same and use thereof | NOVO NORDISK AS (DK) | 1999-07-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040148-A1 | THERAPEUTICS FOR THE TREATMENT OF GLAUCOMA | KCNJ1, KCNJ2, KCNJ11 | LRRK2 2470/4885PTGS2 163/4885ALOX5 1171/4885 |
| US-20170002040-A1 | NOVEL THERAPEUTICS FOR THE TREATMENT OF GLAUCOMA | KCNJ1, KCNK4, KCNK2 | LRRK2 2305/4885PTGS2 234/4885ALOX5 1258/4885 |
| US-11505572-B2 | Therapeutics for the treatment of glaucoma | KCNJ1, KCNJ2, KCNJ11 | LRRK2 2470/4885PTGS2 163/4885ALOX5 1171/4885 |
| US-10981951-B2 | Therapeutics for the treatment of glaucoma | KCNJ1, KCNJ2, KCNJ11 | LRRK2 2470/4885PTGS2 163/4885ALOX5 1171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.